Agreements reached under this partnership
Business Alliance- 1
Embolization efficacy: The high-density mesh structure made of nitinol, a nickel-titanium alloy, together with the proprietary single- and multi-lobe designs, is expected to enable rapid vascular embolization with a single device.
- 2
Enhanced minimally invasive treatment: Compared with conventional techniques using multiple metal coils, embolization can be completed with fewer devices, helping shorten procedure times and reduce radiation exposure from X-ray fluoroscopy.
- 3
Safety and usability: The device is designed to allow retrieval and repositioning before deployment, supporting more accurate positioning and safer procedures.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
| Item | Details |
|---|---|
| Name of alliance partner | Abbott Medical Japan LLC |
| Alliance partner's business activities | Import and sale of medical devices and related products |
| Alliance partner's location | Minato-ku, Tokyo |
| Type of alliance | Business Alliance |
| Details of the alliance | Embolization efficacy: The high-density mesh structure made of nitinol, a nickel-titanium alloy, together with the proprietary single- and multi-lobe designs, is expected to enable rapid vascular embolization with a single device., Enhanced minimally invasive treatment: Compared with conventional techniques using multiple metal coils, embolization can be completed with fewer devices, helping shorten procedure times and reduce radiation exposure from X-ray fluoroscopy., Safety and usability: The device is designed to allow retrieval and repositioning before deployment, supporting more accurate positioning and safer procedures. |
| Alliance start date | 1 August 2026 (scheduled) |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The purpose is to expand the product lineup in the field of endovascular treatment and introduce products with significant clinical value. The company stated that it will use its nationwide sales network to ensure a stable supply of the product and strengthen its ability to provide solutions in the interventional field.